Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL201 vs Topotecan in Relapsed Small Cell Lung Cancer
NCT06612151Phase 3Active, not recruiting
- Sponsor
- MediLink Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in small cell lung cancer (SCLC), sponsored by MediLink Therapeutics. Started Dec 2024; status: active, not recruiting.
02
Drugs
YL201
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06612151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06612151.